Acadia Pharmaceuticals Inc. · NASDAQ:ACAD
Acadia Pharmaceuticals — Q3 2022 Earnings Presentation
23 slides from Acadia Pharmaceuticals's earnings presentation, Nov 2, 2022
Slide 1: Third Quarter 2022 Earnings Call
Third Quarter 2022 Earnings Call November 2, 2022
Slide 2: 3Q22 Earnings Call Agenda
3Q22 Earnings Call Agenda Introduction Mark Johnson | Vice President, Investor Relations CEO Opening Remarks Steve Davis | Chief Executive Officer Commercial Update Brendan Teehan | Chief Operating Officer, Head of Commercial Trofinetide Update Kathie M. Bishop, Ph.D. | Chief Scientific Officer and
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future r
Slide 4: CEO Opening Remarks
CEO Opening Remarks Steve Davis CEO
Slide 5: Acadia's Growth Strategy
Acadia’s Growth Strategy Grow and Maximize Value of Deliver Trofinetide Develop the Next Wave NUPLAZID® Franchise to Rett Community of Breakthroughs Building a Leading CNS Company NUPLAZID (pimavanserin) is only approved in the U.S. by the FDA for the treatment of hallucinations and delusions associ
Slide 6: Drive Growth of NUPLAZID in PDP
Drive Growth of NUPLAZID® in PDP Net Sales Delivered net sales of $130.7M in 3Q22 • NUPLAZID demand growth of 2% QoQ • Inventory reduction in 3Q impacted net sales by approximately -$7M • Early signs of improvement in the long-term care channel Market • In-office channel is unchanged Dynamics • Focu
Slide 7: Advancing Late-Stage Opportunities
Advancing Late-Stage Opportunities Rett syndrome Negative Symptoms of Schizophrenia (Trofinetide) (Pimavanserin) • PDUFA date assigned: March 12, 2023 • Positive pivotal study, ADVANCE-1 • Priority review granted; no AdCom planned • Evaluating 34 mg dose of pimavanserin in second pivotal study, ADVA
Slide 8: Develop the Next Wave of Breakthroughs
Develop the Next Wave of Breakthroughs Program Indication Preclinical Phase 1 Phase 2 Phase 3 Registration Marketed NUPLAZID® Parkinson’s (pimavanserin)1 Disease Psychosis Trofinetide2 Rett Syndrome Negative Pimavanserin Symptoms of Schizophrenia Neuropsychiatric ACP-204 Indications SYNGAP1; ASO Pro
Slide 9: Commercial Update
Commercial Update Brendan Teehan Chief Operating Officer, Head of Commercial
Slide 10: Drive Growth and Maximize Value of NUPLAZID
Drive Growth and Maximize Value of NUPLAZID® PDP Market Dynamics Early Signs of Recovery in LTC Channel $130.7M in net sales in 3Q22; demand growth up 2% QoQ Occupancy Rate and NUPLAZID TRXs in LTC • LTC channel shows early signs of improvement; NUPLAZID outperforming Pre-pandemic early recovery in
Slide 11: Trofinetide Pre-Launch Activities Ongoing
Trofinetide Pre-Launch Activities Ongoing Disease State • Drive understanding of Rett syndrome and the unmet needs of core symptoms, Awareness and Education such as hand wringing, purposeful eye gaze and communication Build-out • Hiring seasoned leadership team with rare disease expertise Rare Disea
Slide 12: Trofinetide Update
Trofinetide Update Kathie Bishop CSO and Head of Rare Disease
Slide 13: Trofinetide for the Treatment of Rett Syndrome
Trofinetide for the Treatment of Rett Syndrome No FDA-approved drug for the treatment of Rett syndrome • Estimated 6,000 to 9,000 patients in the U.S.1 • ~4,500 patients diagnosed and treated for Rett in the U.S. today Debilitating Symptoms2: • Fine and gross motor impairment, hand stereotypies • Lo
Slide 14: R&D Update
R&D Update Serge Stankovic President
Slide 15: Pimavanserin for the Treatment of the Negative Symptoms of Schizophrenia
Pimavanserin for the Treatment of the Negative Symptoms of Schizophrenia No FDA-approved treatment for the negative symptoms of schizophrenia • Estimated 700K+ patients receiving treatment in the U.S. for schizophrenia have persistent negative symptoms Negative symptoms include apathy, lack of emoti
Slide 16: ACP-204: Leveraging the Learnings from Pimavanserin
ACP-204: Leveraging the Learnings from Pimavanserin Program Objectives • Leverage 5-HT2A benefits and favorable safety/tolerability profile • Minimize or eliminate QT signal • Maximize the efficacy profile • Improve onset of action Phase 1 Development • Phase 1 ongoing; evaluating higher dose ranges
Slide 17: Finance Update
Finance Update Mark Schneyer Chief Financial Officer
Slide 18: 3Q22 Financial Highlights
3Q22 Financial Highlights 3Q22 3Q21 YoY YTD-22 YTD-21 YoY Millions, Except EPS (GAAP) (GAAP) Change (GAAP) (GAAP) Change Total Revenue $130.7 $131.6 -1% $380.7 $353.4 +8% R&D $81.31 $58.6 +39% $285.82 $172.5 +66% SG&A $78.1 $81.7 -4% $264.7 $290.1 -9% Net Income (Loss) ($27.2) ($14.5) ($174.3) ($124
Slide 19: Overall Impact of IRA for NUPLAZID Franchise
Overall Impact of IRA for NUPLAZID Franchise The overall impact of the Inflation Reduction Act (IRA) on NUPLAZID franchise value is modest 1. Pricing realization related to Medicare patients limited to inflation-adjusted 2021 price 2. Medicare Part D beneficiaries will benefit from improved access w
Slide 20: FY22 Financial Guidance
FY22 Financial Guidance Previous Updated FY22 Guidance FY22 Guidance Commentary (8/8/2022) (11/2/2022) NUPLAZID® • Midpoint reflects similar demand levels, $510 to $540M $510 to $520M Net Sales 3Q inventory reduction and impact from IRA NUPLAZID 19.5% - 20.5% 21% - 22% • Due to accruing for future M
Slide 21: CEO Closing Remarks
CEO Closing Remarks Steve Davis CEO
Slide 22: Building a Leading CNS Company
Building a Leading CNS Company Key Strengths: • Established infrastructure, commercial teams, clinical development Advance Late-Stage and • Committed to investing in Early-Stage Pipeline high-value CNS opportunities Execute Business Development • Optimized spend with focus Launch Potential on positi
Slide 23: Q&A Session
() ACADIA Q&A Session
ACADIA Pharmaceuticals — Q3 2022 Earnings Presentation on 6ix